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ABSTRACT:  Δ9-Tetrahydrocannabinolic acid A (Δ9-THCA-A) is the biosynthetic precursor of Δ9-tetrahydrocannabinol (Δ9-
THC) in plant material of cannabis sativa, without having psychoactive effects . Δ9-THCA-A is not contained in pharmaceutical 
Δ9-THC formulations. Thus, Δ9-THCA-A can serve as a marker for differentiating between the consumption of illegal cannabis 
products and legal fully synthetic Δ9-THC. 
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Cannabis is the most popular recreational drug globally 1. 
The resin of Cannabis plant contains more than 84 chemical 
compounds with psychoactive effects, known as 
cannabinoids, the most efficacious of which is Δ9-
tetrahydrocannabinol (Δ9-THC)2. The biogenesis of Δ9-
THC starts with olivetolic acid, that is produced in the plant 
from the condensation of hexanoyl-CoA with three 
molecules of malonyl-CoA. In the next step, olivetolic acid 
is alkylated to cannabigerolic acid, which is then converted 
to cannabinolic acid. Cannabinolic acid is the precursor of 
Δ9-tetrahydrocannabinolic acid A (Δ9-THCA-A or Δ9-
THCA). Δ9-THCA-A is a non-psychoactive substance that 
is decarboxylated to Δ9-THC via heating, when cannabis 
products are smoked 3.  
The therapeutic effects of Δ9-THC have been known since 
ancient times,  when cannabis was used as a medicine for 
many different pathological conditions such as insomnia, 
headaches, gastrointestinal disorders and pain 4. Nowadays 
the cultivation,  
possession and transfer of cannabis is illegal in most of the 
European countries and is convicted by law. On the other 
hand, medical Δ9-THC is provided, mainly in the U.S, to 
treat a range of diseases and the ensuing symptoms. 
Marinol® (U.S, Canada) is an oral drug containing fully 
synthetic  Δ9-THC, known as dronabinol and is used to treat 
anorexia in people suffering from AIDS, and also to 
minimize nausea and vomiting associated with cancer 
therapy5.  Another popular pharmaceutical compound, used 
to treat spasticity and neuropathic pain associated with 
multiple schlerosis, is Sativex® (U.S, Europe, New 
Zealand). Sativex® is an oromucosal spray which contains 
nabiximols, a mixture of compounds derived from cannabis 
plant. The principal cannabinoid components of the drug 
are synthetic Δ9-THC and cannabidiol 6.  
 The high popularity of illegal cannabis and the use of legal 
fully synthetic Δ9-THC in recent years, demonstrated the 
need to find reliable markers in biological samples for 
differentiating between the consumption of illegal cannabis 
products and legal medication containing fully synthetic Δ9-
THC.  
Δ9-THCA-A could serve as a marker of illegal consumption 
of cannabis products if the substance is detected in 
biological samples of cannabis users. Δ9-THCA-A attracted 
scientists' attention in recent years, as it is the precursor 
substance of natural Δ9-THC in plant material and is not 
contained in Marinol® or Sativex®. In 2005, it was shown 
that during smoking cannabis joint, Δ9-THCA-A is only 
partially converted to Δ9-THC and therefore it can be taken 
up by the consumer 7.  
In 2007, Jung et al. detected Δ9-THCA-A in the urine and 
blood serum samples collected from police controls of 
drivers suspected for driving under the influence of drugs 
(DUID). Liquid chromatography tandem-mass 
spectrometry (LC-MS/MS) was used for Δ9-THCA-A 
determination. Δ9-THCA-A was detected in the urine and 
blood serum samples of cannabis users in concentrations of 
up to 10.8 ng/ml in urine and 14.8 ng/ml in serum. The 
concentration of Δ9-THC was higher than the concentration 
of Δ9-THCA-A in most serum samples 8. In the above 
paper, Δ9-THCCOOH-D3 was used as internal standard 
(IS) because the isotopically labeled Δ9-THCA-A was not 
commercially available.  
In 2012, Roth et al. succeeded to synthesize deuterated Δ9-
THCA-A 9. Metabolism studies of Δ9-THCA-A in rats 
showed that the main metabolites of THCA-A were formed 
in close analogy to Δ9-THC metabolism and twelve 
metabolites were identified 10.  
  In 2013, Brabanter N. et al. developed a fast method for 
quantification of Δ9-THCA-A in urine using microwave-
accelerated derivatization and gas chromatography–triple 
quadrupole mass spectrometry. Their method could 
quantify Δ9-THCA-A in 30 min, using only 1 mL of urine 
11. 
In 2013, Raikos N. et al. analyzed fifty eight authentic 
whole blood and the respective plasma samples collected 
from drivers suspected for driving under the influence of 
cannabis, using LC-MS/MS. Δ9-THCA-A concentrations 
ranged from 1.0 to 496 ng/mL in blood samples and from 
1.4 to 824 ng/mL in plasma samples. Δ9-THC was present 
in all blood samples with levels ranging from 0.7 to 51 
ng/mL. The plasma:blood partition coefficient had a mean 
value of 1.7  12. 
In 2010, Auwarter et al. concluded that Δ9-THCA-A can  be 
incorporated in hair only by external contamination e.g. by 
condensate of smoked cannabis material and not by blood 
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or sweat and Δ9-THCA-A could be a valuable marker for 
external cannabinoid contamination of hair 13. 
In conclusion, Δ9-THCA-A can be detected in blood and 
urine samples of cannabis consumers and this detection in 
biological fluids may serve as a marker for differentiating 
between the intake of legally prescribed Δ9-THC 
medication and illegal cannabis products. However, the 
knowledge about its usefulness in forensic cases is very 
limited and further research is needed. 
 
 
Δ9-τετραϋδροκανναβινολικό οξύ Α: ένας αξιόπιστος δείκτης για τη 
διάκριση μεταξύ της χρήσης παράνομων προϊόντων της κάνναβης 
και της λήψης φαρμακευτικής  Δ9-THC. 
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ΠΕΡΙΛΗΨΗ: Το Δ9-τετραϋδροκανναβινολικό οξύ Α (Δ9-THCA-A) αποτελεί την πρόδρομη ουσία της Δ9-
τετραϋδροκανναβινόλης (Δ9-THC) στο φυτό cannabis sativa,  χωρίς ψυχοδραστικές ιδιότητες. Το Δ9-THCA-A δεν 
εμπεριέχεται στα φαρμακευτικά προϊόντα που περιέχουν συνθετική Δ9-THC. Συνεπώς το Δ9-THCA-A μπορεί να 
χρησιμεύσει ως ένας δείκτης για τη διάκριση μεταξύ της χρήσης παράνομων προϊόντων της κάνναβης και της λήψης 
φαρμακευτικής  Δ9-THC. 
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